Rinatabart Sesutecan for Patients With Platinum-Resistant Ovarian Cancer: First Efficacy and Safety Results From the Phase 2 Cohort of the RAINFOL-01 Study
Published: | Updated:
Elizabeth K. Lee, MD, of Dana-Farber Cancer Institute in Boston, Massachusetts, reviews the first efficacy and safety results from the phase 2 cohort of the RAINFOL-01 study of rinatabart sesutecan, a folate receptor alpha (FRα)-directed antibody-drug conjugate, in patients with platinum-resistant ovarian cancer, as presented at the 2026 International Gynecologic Cancer Society Annual Global Meeting.